BioMedPartners AG

BioMedPartners AG is an independent European venture capital firm based in Basel, Switzerland, focusing on providing private equity and mezzanine financing to early-to-mid-stage healthcare and life-science companies. Since its establishment in 2002, the firm has managed over CHF 350 million in capital and invested in more than 55 portfolio companies. Their investment strategy emphasizes sectors such as biotechnology, medical devices, pharmaceuticals, healthcare, and life sciences, with a geographical focus on Switzerland, Germany, France, Italy, and the Benelux countries. The firm typically invests between CHF 1 million and CHF 10 million in early-stage companies, including Series A, Series B, and growth stages. Notable portfolio companies include Amal Therapeutics SA, Okairos AG, SuppreMol GmbH, Glycart Technology AG, and ESBATech AG. BioMedPartners AG is recognized as one of the leading early-stage healthcare investors in Europe, leveraging a strong team of experienced industry experts and an extensive scientific and pharmaceutical network to support the growth and success of its portfolio companies.

The firm's investment approach is characterized by a hands-on strategy, working closely with portfolio companies to develop and implement growth and exit strategies. This collaborative approach aims to maximize alignment of interests between BioMedPartners AG and the management teams of its investee companies. The firm has a track record of successful exits, with several portfolio companies having been acquired by leading biopharmaceutical companies or having completed initial public offerings. This success underscores BioMedPartners AG's expertise in identifying and nurturing innovative healthcare and life-science ventures.

BioMedPartners AG's commitment to the healthcare sector is further demonstrated by its active participation in the Swiss Biotech Association, reflecting its dedication to advancing the life sciences industry in Switzerland and Europe. The firm's strategic focus on early-to-mid-stage investments allows it to play a pivotal role in the development and commercialization of groundbreaking healthcare solutions, contributing to the overall advancement of medical science and patient care.